Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Government to conduct...

    Government to conduct study to assess impact of FDI in pharma industry

    Written by savita thakur thakur Published On 2016-05-30T16:51:22+05:30  |  Updated On 30 May 2016 4:51 PM IST

    NEW DELHI: The Commerce and Industry Ministry has commissioned a study to assess the impact of foreign direct investment in pharmaceutical companies amid concerns over mergers and acquisitions of domestic drug manufacturers.


    "An expert from academic field has been engaged in this exercise along with the National Productivity Council," an official said.

    The report is expected to be submitted in the next three to four months.

    The experts would look into issues like the impact of foreign direct investment in the brownfield pharmaceutical companies and access to affordable medicines, the official said, adding access to medicines can be ensured only when India would have a strong generic medicine industry.

    The mergers and acquisitions of Indian pharmaceutical companies by foreign giants could impact the accessibility and growth of generic industry, another source said.

    A report of the Parliamentary Standing Committee on Commerce had suggested that a study group be set up to investigate the effect of FDI in brownfield pharma or operational firms.

    There are apprehensions that takeovers by multi-national firms have impacted the generic medicine industry of the country.

    The Committee had said that the government should impose a blanket ban on any FDI in brownfield pharma projects.

    It had also suggested for measures to stop any further take over/acquisition of domestic pharma units.

    "In many countries, takeovers are not allowed in strategic sectors like pharma. For India, affordable healthcare is a challenge and for that access to medicines is important," said an industry expert.

    As per the current policy, 100 per cent FDI is permitted in the existing pharma companies through the approval route. 100 per cent FDI is also allowed in greenfield (new) projects.

    India is recognised as a major generic medicine hub of the world. The market size of the country's pharma industry is estimated at over $20 billion.

    In 2008, Japanese firm Daiichi Sankyo had bought out the country's largest drug maker Ranbaxy for $4.6 billion.

    US-based Abbot Laboratories had acquired Piramal Health Care's domestic business for $3.7 billion. Another US company Mylan bought Matrix Lab while Dabur Pharma was acquired by Singapore's Fresenius and France's Sanofi Aventis purchased Shanta Biotech and certain assets of Orchid Chemicals were acquired by US-based Hospira.

    As per estimates, over 96 per cent of the total FDI in the sector between April 2012 and April 2013 came into the brownfield pharma companies.
    Dabur PharmaDaiichi SankyoFDIforeign direct investmenthospiraMylan pharmaPharma IndustryPiramalRanbaxySanofi
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok